<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31872">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02030418</url>
  </required_header>
  <id_info>
    <org_study_id>DC-02374</org_study_id>
    <nct_id>NCT02030418</nct_id>
  </id_info>
  <brief_title>The LEADLESS II IDE</brief_title>
  <official_title>Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, single-arm, international multicenter, clinical safety and
      effectiveness investigation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complication-Free Rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pacing thresholds and R-wave amplitudes within the therapeutic range</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>appropriate and proportional rate response during graded exercise testing</measure>
    <time_frame>3-6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">667</enrollment>
  <condition>Subjects Who Are Indicated for a VVI(R) Pacemaker.</condition>
  <arm_group>
    <arm_group_label>Leadless Pacemaker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Leadless Pacemaker</intervention_name>
    <arm_group_label>Leadless Pacemaker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have one of the clinical indications in adherence with Medicare,
             ACC/AHA/HRS/ESC single chamber pacing guidelines including:

               -  Chronic and/or permanent atrial fibrillation with 2 or 3° AV or bifascicular
                  bundle branch block (BBB block), including slow ventricular rates (with or
                  without medication) associated with atrial fibrillation; or

               -  Normal sinus rhythm with 2 or 3° AV or BBB block  and a low level of physical
                  activity or short expected lifespan (but at least one year); or

               -  Sinus bradycardia with infrequent pauses or unexplained syncope with EP
                  findings; and

          2. Subject ≥18 years of age; and

          3. Subject has life expectancy of at least one year; and

          4. Subject is not enrolled in another clinical investigation; and

          5. Subject is willing to comply with clinical investigation procedures and agrees to
             return for all required follow-up visits, tests, and exams; and

          6. Subject has been informed of the nature of the study, agrees to its provisions and
             has provided written informed consent, approved by the IRB; and

          7. Subject is not pregnant and does not plan to get pregnant during the course of the
             study.

        Exclusion Criteria:

          1. Subject has pacemaker syndrome, has retrograde VA conduction or suffers a drop in
             arterial blood pressure with the onset of ventricular pacing; or

          2. Subject is allergic or hypersensitive to &lt;1 mg of dexamethasone sodium phosphate; or

          3. Subject has a mechanical tricuspid valve prosthesis; or

          4. Subject has a pre-existing pulmonary arterial (PA) hypertension (PA systolic pressure
             exceeds 40 mmHg or RV systolic pressure (RVSP) as estimated by echo exceeds 40 mmHg),
             or significant physiologically-impairing lung disease; or

          5. Subject has a pre-existing pacing or defibrillation leads; or

          6. Subject has current implantation of either conventional or subcutaneous implantable
             cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT); or

          7. Subject has an implanted vena cava filter; or

          8. Subject has evidence of thrombosis in one of the veins used for access during the
             procedure; or

          9. Subject has an implanted leadless cardiac pacemaker.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Reddy, MD</last_name>
      <phone>212-741-7272</phone>
      <email>vivek.reddy@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Srinivas Dukkipati, MD</last_name>
      <phone>(212) 741-7272</phone>
      <email>srinivas.dukkipati@mountsinai.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
